TNF-α inhibitors, such as adalimumab, used in the treatment of HS, are not associated with an increased risk of developing cSCC, suggesting that TNF-α is not directly involved in cSCC development [18]. The gene discussed is TNF; the disease is histiocytic sarcoma.